NO854122L - Fremgangsm¨te for fremstilling av et nytt lymfokin. - Google Patents

Fremgangsm¨te for fremstilling av et nytt lymfokin.

Info

Publication number: NO854122L
Authority: NO; Norway
Prior art keywords: cells; human; lymphokine; activity; cell
Prior art date: 1984-10-19

Application number

NO854122A

Other languages

English (en)

Norwegian (no)

Inventor

Toshiaki Ohsawa

Yoshiro Kobayashi

Makoto Asada

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-19

Filing date

1985-10-17

Publication date

1986-04-21

1985-10-17 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1986-04-21 Publication of NO854122L publication Critical patent/NO854122L/no

Links

238000000034 method Methods 0.000 title claims description 22
238000002360 preparation method Methods 0.000 title description 3
206010025323 Lymphomas Diseases 0.000 title 1
210000004027 cell Anatomy 0.000 claims description 52
230000000694 effects Effects 0.000 claims description 49
210000001744 T-lymphocyte Anatomy 0.000 claims description 37
210000000822 natural killer cell Anatomy 0.000 claims description 29
210000004408 hybridoma Anatomy 0.000 claims description 24
108010002350 Interleukin-2 Proteins 0.000 claims description 15
102000000588 Interleukin-2 Human genes 0.000 claims description 15
230000003213 activating effect Effects 0.000 claims description 9
102000014150 Interferons Human genes 0.000 claims description 8
108010050904 Interferons Proteins 0.000 claims description 8
229940079322 interferon Drugs 0.000 claims description 8
210000005259 peripheral blood Anatomy 0.000 claims description 5
239000011886 peripheral blood Substances 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 4
108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
102000008072 Lymphokines Human genes 0.000 description 13
108010074338 Lymphokines Proteins 0.000 description 13
229920003023 plastic Polymers 0.000 description 13
239000004033 plastic Substances 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
239000002609 medium Substances 0.000 description 12
238000004113 cell culture Methods 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000000853 adhesive Substances 0.000 description 10
230000001070 adhesive effect Effects 0.000 description 9
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
239000003480 eluent Substances 0.000 description 8
102000004083 Lymphotoxin-alpha Human genes 0.000 description 7
108090000542 Lymphotoxin-alpha Proteins 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
239000012980 RPMI-1640 medium Substances 0.000 description 6
229960000640 dactinomycin Drugs 0.000 description 6
230000006870 function Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
108060003552 hemocyanin Proteins 0.000 description 4
229960004857 mitomycin Drugs 0.000 description 4
210000005087 mononuclear cell Anatomy 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000006051 NK cell activation Effects 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
238000003113 dilution method Methods 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000700605 Viruses Species 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
HUEYSSLYFJVUIS-MRFSYGAJSA-N (2s,3r,11bs)-2-[[(1r)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine;hydron;chloride Chemical compound Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC HUEYSSLYFJVUIS-MRFSYGAJSA-N 0.000 description 1
OQPDPIPLWCUACY-UHFFFAOYSA-N 2-aminoethylthiourea;hydrobromide Chemical compound [Br-].NCC[NH+]=C(N)S OQPDPIPLWCUACY-UHFFFAOYSA-N 0.000 description 1
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
101001051524 Parabuthus granulatus Toxin PgKL2 Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000269841 Thunnus albacares Species 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229960001923 emetine hydrochloride Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)

NO854122A 1984-10-19 1985-10-17 Fremgangsm¨te for fremstilling av et nytt lymfokin. NO854122L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP59218643A JPS6197224A (ja)	1984-10-19	1984-10-19	新規なリンホカイン

Publications (1)

Publication Number	Publication Date
NO854122L true NO854122L (no)	1986-04-21

Family

ID=16723161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO854122A NO854122L (no)	1984-10-19	1985-10-17	Fremgangsm¨te for fremstilling av et nytt lymfokin.

Country Status (3)

Country	Link
EP (1)	EP0181524A3 (de)
JP (1)	JPS6197224A (de)
NO (1)	NO854122L (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0631318B2 (ja) *	1985-09-18	1994-04-27	株式会社林原生物化学研究所	新リンホカインｉｉｉとその製法
US5185431A (en) *	1988-08-31	1993-02-09	Eisai Co., Ltd.	Recombinant natural killer cell activator

1984
- 1984-10-19 JP JP59218643A patent/JPS6197224A/ja active Pending
1985
- 1985-10-17 NO NO854122A patent/NO854122L/no unknown
- 1985-10-18 EP EP85113254A patent/EP0181524A3/de not_active Withdrawn

Also Published As

Publication number	Publication date
JPS6197224A (ja)	1986-05-15
EP0181524A3 (de)	1988-12-14
EP0181524A2 (de)	1986-05-21

Publication	Publication Date	Title
Mingari et al.	1984	Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells
AU688056B2 (en)	1998-03-05	Surface complexed lymphotoxin
Martens et al.	1985	cDNA clones encoding IgE-binding factors from a rat-mouse T-cell hybridoma.
Shimizu et al.	1985	Immortalization of BGDF (BCGF II)-and BCDF-producing T cells by human T cell leukemia virus (HTLV) and characterization of human BGDF (BCGF II).
Schreiber	1984	Identification of gamma-interferon as a murine macrophage-activating factor for tumor cytotoxicity
Erard et al.	1984	Characterization of soluble factors that induce the cytolytic activity and the expression of T cell growth factor receptors of a T cell hybrid.
JPS5928492A (ja)	1984-02-15	細胞培養系よりの血しよう蛋白質の分離
EP0291728A2 (de)	1988-11-23	Herstellung von Immun-Interferon und seiner m-RNS
Hirashima et al.	1981	Formation of IgE-binding factors by rat T lymphocytes. III. Mechanisms of selective formation of IgE-suppressive factors by treatment with complete Freund's adjuvant.
Yasukawa et al.	1993	Expression of perforin and membrane-bound lymphotoxin (tumor necrosis factor-beta) in virus-specific CD4+ human cytotoxic T-cell clones
Suciu-Foca et al.	1984	Reactivity of HTLV-transformed human T-cell lines to MHC class II antigens
US6265214B1 (en)	2001-07-24	Methods and compositions for inducing monocyte cytotoxicity
Ralph et al.	1980	Functions of macrophage cell lines
Boylston et al.	1985	Growth of normal human T lymphocytes induced by monoclonal antibody to the T cell antigen receptor
JPS60112718A (ja)	1985-06-19	抗腫瘍作用を示す蛋白性物質及びその製造方法
CN108285493B (zh)	2020-09-15	一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
NO854122L (no)	1986-04-21	Fremgangsm¨te for fremstilling av et nytt lymfokin.
US5330896A (en)	1994-07-19	Monoclonal antibodies to an autocrine growth factor antigen that binds to activated lymphocytes and cancer cells
JPS5849319A (ja)	1983-03-23	マイトジエンおよびその単離方法
Higuchi et al.	1984	Macrophage-activating factor for cytotoxicity produced by a human T-cell hybridoma
Yamasaki et al.	1984	Establishment of experimental malignant glioma-specific cytotoxic T lymphocyte clone by T cell growth factor
Yamanaka et al.	1989	Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta.
Grönvik et al.	1982	A stable TCGF-producing T cell hybridoma and its thioguanine-resistant variant suitable as a tool for the construction of new functional T hybridomas
Tanaka et al.	1985	Production and characterization of tumor-degenerating factor
CA1295241C (en)	1992-02-04	Lymphokine and its production and uses